Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma
Key clinical point: Axicabtagene ciloleucel (axi-cel) can be safely administered and has substantial clinical benefit as part of first-line therapy in patients with high-risk LBCL.
Major finding: The overall response rate was 85% and complete response rate was 74%; with a median follow-up of 9.3 months, 70% of responders were in ongoing response.
Study details: Interim analysis of ZUMA-12, a phase 2 study with a planned enrollment of 40 patients with high-risk LBCL.
Disclosures: ZUMA-12 is sponsored by Kite, a Gilead Company. Dr. Neelapu reported disclosures related to Acerta; Adicet Bio; Bristol-Myers Squibb; Kite, a Gilead Company; and various other pharmaceutical and biotechnology companies.
Neelapu SS et al. ASH 2020, Abstract 405.